Novo Nordisk Signs Diabetes and Obesity Collaboration with Kallyope
By Jawala Prasad
Pharma Deals Review: Vol 2018 Issue 7 (Table of Contents)
Published: 4 Jul-2018
DOI: 10.3833/pdr.v2018.i7.2334 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing its lookout for promising assets after its failed bid to acquire Belgian company, Ablynx, Novo Nordisk has entered into a research collaboration to develop peptide therapeutics with Kallyope for the treatment of diabetes and obesity...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS